Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/08/01 | 961 | 969 | 913 | 925 | -43 | -4.4% | 123,500 |
| 2022/07/29 | 952 | 968 | 942 | 968 | +17 | +1.8% | 64,700 |
| 2022/07/28 | 969 | 983 | 948 | 951 | -5 | -0.5% | 53,000 |
| 2022/07/27 | 951 | 960 | 941 | 956 | +7 | +0.7% | 32,500 |
| 2022/07/26 | 946 | 970 | 935 | 949 | +3 | +0.3% | 72,300 |
| 2022/07/25 | 995 | 1,012 | 942 | 946 | -79 | -7.7% | 262,100 |
| 2022/07/22 | 1,102 | 1,102 | 1,023 | 1,025 | -77 | -7% | 175,700 |
| 2022/07/21 | 1,116 | 1,126 | 1,097 | 1,102 | +3 | +0.3% | 81,400 |
| 2022/07/20 | 1,140 | 1,145 | 1,097 | 1,099 | -26 | -2.3% | 64,700 |
| 2022/07/19 | 1,118 | 1,139 | 1,083 | 1,125 | +12 | +1.1% | 43,900 |
| 2022/07/15 | 1,121 | 1,128 | 1,095 | 1,113 | -8 | -0.7% | 47,500 |
| 2022/07/14 | 1,063 | 1,121 | 1,059 | 1,121 | +44 | +4.1% | 52,700 |
| 2022/07/13 | 1,103 | 1,103 | 1,067 | 1,077 | -33 | -3% | 75,200 |
| 2022/07/12 | 1,112 | 1,121 | 1,088 | 1,110 | -16 | -1.4% | 50,600 |
| 2022/07/11 | 1,126 | 1,131 | 1,101 | 1,126 | +18 | +1.6% | 34,900 |
| 2022/07/08 | 1,118 | 1,132 | 1,081 | 1,108 | -11 | -1% | 105,900 |
| 2022/07/07 | 1,134 | 1,134 | 1,090 | 1,119 | -7 | -0.6% | 64,400 |
| 2022/07/06 | 1,102 | 1,150 | 1,084 | 1,126 | +33 | +3% | 124,300 |
| 2022/07/05 | 1,142 | 1,142 | 1,075 | 1,093 | -22 | -2% | 80,300 |
| 2022/07/04 | 1,060 | 1,118 | 1,059 | 1,115 | +67 | +6.4% | 109,500 |
| 2022/07/01 | 1,049 | 1,053 | 1,018 | 1,048 | ±0 | ±0% | 82,200 |
| 2022/06/30 | 1,079 | 1,091 | 1,033 | 1,048 | -26 | -2.4% | 75,100 |
| 2022/06/29 | 1,074 | 1,090 | 1,055 | 1,074 | -30 | -2.7% | 67,400 |
| 2022/06/28 | 1,076 | 1,128 | 1,066 | 1,104 | +19 | +1.8% | 95,600 |
| 2022/06/27 | 1,149 | 1,160 | 1,083 | 1,085 | -68 | -5.9% | 161,300 |
| 2022/06/24 | 1,121 | 1,160 | 1,104 | 1,153 | +56 | +5.1% | 185,100 |
| 2022/06/23 | 1,045 | 1,104 | 1,040 | 1,097 | +54 | +5.2% | 162,800 |
| 2022/06/22 | 1,045 | 1,053 | 995 | 1,043 | +13 | +1.3% | 113,600 |
| 2022/06/21 | 984 | 1,039 | 983 | 1,030 | +58 | +6% | 131,300 |
| 2022/06/20 | 934 | 980 | 931 | 972 | +50 | +5.4% | 116,200 |
| 2022/06/17 | 902 | 960 | 898 | 922 | -14 | -1.5% | 135,600 |
| 2022/06/16 | 927 | 953 | 917 | 936 | +17 | +1.8% | 101,300 |
| 2022/06/15 | 916 | 947 | 899 | 919 | +3 | +0.3% | 91,300 |
| 2022/06/14 | 882 | 916 | 874 | 916 | +4 | +0.4% | 101,500 |
| 2022/06/13 | 924 | 924 | 894 | 912 | -42 | -4.4% | 140,400 |
| 2022/06/10 | 942 | 960 | 918 | 954 | -3 | -0.3% | 160,600 |
| 2022/06/09 | 992 | 999 | 950 | 957 | -33 | -3.3% | 300,300 |
| 2022/06/08 | 1,038 | 1,069 | 948 | 990 | +71 | +7.7% | 1,645,000 |
| 2022/06/07 | 900 | 938 | 893 | 919 | -5 | -0.5% | 106,300 |
| 2022/06/06 | 906 | 951 | 901 | 924 | +13 | +1.4% | 117,600 |
| 2022/06/03 | 877 | 921 | 868 | 911 | +36 | +4.1% | 153,600 |
| 2022/06/02 | 873 | 888 | 839 | 875 | +2 | +0.2% | 118,800 |
| 2022/06/01 | 903 | 920 | 869 | 873 | -45 | -4.9% | 134,200 |
| 2022/05/31 | 883 | 924 | 871 | 918 | +24 | +2.7% | 213,900 |
| 2022/05/30 | 823 | 897 | 810 | 894 | +79 | +9.7% | 235,000 |
| 2022/05/27 | 845 | 874 | 801 | 815 | -16 | -1.9% | 669,700 |
| 2022/05/26 | 767 | 864 | 760 | 831 | +73 | +9.6% | 914,900 |
| 2022/05/25 | 795 | 795 | 749 | 758 | -41 | -5.1% | 165,500 |
| 2022/05/24 | 830 | 832 | 792 | 799 | -42 | -5% | 113,600 |
| 2022/05/23 | 803 | 848 | 798 | 841 | +52 | +6.6% | 144,300 |
751～
800
件表示中 / 1674件
類似銘柄と比較する
現在ご覧いただいている「ＤＥＬＴＡ－Ｐ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＤＥＬＴＡ－Ｐ | 62,800円 | - | - | 0.00% | - | 26.32倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
| ケイファーマ | 69,500円 | - | - | 0.00% | - | 4.45倍 |
|
慶応大学発ベンチャー。ｉＰＳ細胞による再生医療と創薬の２本柱。中枢神経系が得意領域 |
| シンバイオ | 15,100円 | -42.9% | - | 0.00% | - | 3.64倍 |
|
導入で新薬開発・製品化。抗がん剤「トレアキシン」国内販売。抗ウイルス薬ＢＣＶの開発に注力 |
| ティムス | 15,700円 | - | - | 0.00% | - | 2.56倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補を中国ＣＯＲＸＥＬ社に導出 |
| 日ケミファ | 161,100円 | +7.5% | -77.4% | 3.10% | 38.74倍 | 0.30倍 |
|
後発薬中堅、検査薬事業が第２の柱に。提携含めた新薬開発、ベトナムなど海外事業を中期強化 |
市場注目の銘柄
チャート関連のコラム
